Gilead Sciences (GILD) FY2024 10-K Annual Report
Gilead Sciences (GILD) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 28, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Gilead Sciences FY2024 10-K Analysis
Business Overview
- • Core biopharmaceutical model focused on innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, cancer, inflammation
- • Continued emphasis on fixed-dose combination oral HIV therapies like Biktarvy, Genvoya, Descovy, with FDA-approved PrEP indication for Descovy highlighted this year
- • Collaboration with Janssen for co-marketing and revenue sharing on key HIV products such as Odefsey, Complera/Eviplera, and Symtuza maintained and detailed
- • Geographic presence expanded to more than 35 countries with global headquarters in Foster City, California
- • Distinct focus this filing on extensive oral single-tablet HIV regimens, reinforcing leadership in efficient, convenient antiviral treatments
Management Discussion & Analysis
- • Revenue $28.8B, up 6% YoY from $27.1B, driven by HIV, Oncology, Liver Disease sales; Veklury sales declined
- • Net income $480M, down 92% YoY from $5.7B; impacted by $4.2B IPR&D impairment and $3.8B CymaBay acquisition expenses
- • Oncology impaired by $4.2B Trodelvy IPR&D write-down; Liver Disease boosted by $4.3B CymaBay acquisition adding seladelpar
- • Capital allocation included $320M buyout of seladelpar royalties; no specific buybacks or dividends disclosed in excerpt
- • 2025 outlook: expected product demand growth, regulatory approvals for lenacapavir HIV prevention, offset by Inflation Reduction Act impact and foreign exchange losses
Risk Factors
- • FDA regulatory risk from ongoing antitrust probe involving HIV drug price practices by U.S. Federal Trade Commission
- • U.S. market exposure with 70% of total product sales $20.5B concentrated in HIV products, sensitive to U.S. healthcare policy changes
- • Supply chain risk due to reliance on key raw materials for Biktarvy production concentrated in single manufacturing site in Europe
- • Competitive threat from ViiV Healthcare’s Cabotegravir long-acting injectable HIV treatment impacting Gilead’s Biktarvy sales growth
- • Concentration risk with top five products generating over 85% of revenue, potential earnings volatility from single product patent expirations
Gilead Sciences FY2024 Key Financial MetricsXBRL
Revenue
$28.8B
▲ +6.0% YoY
Net Income
$480M
▼ -91.5% YoY
Operating Margin
5.8%
▼ -2227bp YoY
Net Margin
1.7%
▼ -1922bp YoY
ROE
2.5%
▼ -2233bp YoY
Total Assets
$59.0B
▼ -5.0% YoY
EPS (Diluted)
$0.38
▼ -91.6% YoY
Operating Cash Flow
$10.8B
▲ +35.2% YoY
Source: XBRL data from Gilead Sciences FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Gilead Sciences Annual Reports
Get deeper insights on Gilead Sciences
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.